{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wermke M"],"funding":["NCATS NIH HHS","Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)","NCRR NIH HHS","NCI NIH HHS","Cancer Prevention and Research Institute of Texas"],"pagination":["2365-2374"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12283372"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(7)"],"pubmed_abstract":["In contrast to chimeric antigen receptor T cells, T cell receptor (TCR)-engineered T cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02<sup>+</sup> patients with PRAME<sup>+</sup> recurrent and/or refractory solid tumors, including melanoma and sarcoma. Primary objectives include the evaluation of safety and tolerability and the determination of the maximum tolerated dose (MTD) and/or recommended dose for extension. Secondary objective"],"journal":["Nature medicine"],"pubmed_title":["Autologous T cell therapy for PRAME&lt;sup&gt;+&lt;/sup&gt; advanced solid tumors in HLA-A*02&lt;sup&gt;+&lt;/sup&gt; patients: a phase 1 trial."],"pmcid":["PMC12283372"],"funding_grant_id":["L30 CA123720","M01 RR000847","DP150029","UM1 TR004906","R01 CA306089"],"pubmed_authors":["Singh-Jasuja H","Holderried TAW","Krishna D","Mendrzyk R","Reinhardt C","Chatterjee M","Araujo DM","Hossain MB","Fritsche J","Brossart P","Tsimberidou AM","Satelli A","Weinschenk T","Schoor O","Hengler S","Hilf N","Mayer-Mokler A","Wagner C","Britten CM","Aslan K","Wermke M","Jazaeri AA","Reshef R","Bunk S","Mohamed A","Pozo K","Kursunel MA","Luke JJ","Gulde S","Bokemeyer C","Kalra M","Rammensee HG","Walter S","Wetzko K","Backert L","Maurer D","Schuster H","Hukelmann J","Letizia M","Alsdorf W"],"additional_accession":[]},"is_claimable":false,"name":"Autologous T cell therapy for PRAME&lt;sup&gt;+&lt;/sup&gt; advanced solid tumors in HLA-A*02&lt;sup&gt;+&lt;/sup&gt; patients: a phase 1 trial.","description":"In contrast to chimeric antigen receptor T cells, T cell receptor (TCR)-engineered T cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02<sup>+</sup> patients with PRAME<sup>+</sup> recurrent and/or refractory solid tumors, including melanoma and sarcoma. Primary objectives include the evaluation of safety and tolerability and the determination of the maximum tolerated dose (MTD) and/or recommended dose for extension. Secondary objective","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-07-15T12:29:53.288Z","creation":"2025-08-13T03:04:48.385Z"},"accession":"S-EPMC12283372","cross_references":{"pubmed":["40205198"],"doi":["10.1038/s41591-025-03650-6"]}}